Concomitant use of PPIs and antiplatelet therapy

Gastroenterology and Hepatology

Volumn 7, Issue 4, 2011, Pages 7-10

  Johnson, David A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ADRENALIN; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; NAPROXEN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACUTE CORONARY SYNDROME; AGED; ALLELE; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; CLIP; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DIZZINESS; DRUG COMPETITION; DRUG ELUTING STENT; DYSLIPIDEMIA; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOSS OF FUNCTION MUTATION; MALE; MELENA; META ANALYSIS (TOPIC); ORTHOSTATIC HYPOTENSION; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; STENT THROMBOSIS; STOMACH HEMORRHAGE; STOMACH ULCER;

EID: 79955758023     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157.
2. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420. (Pubitemid 35340537)
3. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus Clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol. 2006;4:860-865.
4. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a reporr of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documenrs. Circulation. 2008;118:1894-1909.
5. Shehab N, Sperling LS, Kegler SR, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from Clopidogrel plus aspirin and from warfarin. Arch Intern Med. 2010;170:1926-1933.
6. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of Omeprazol on the antiplatelet action of Clopidogrel associated to aspirin. J Thromb Haemost. 2006;4:2508-2509. (Pubitemid 44575451)
7. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of Clopidogrel associated with aspirin, the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
8. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of Clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
9. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of Clopidogrel after coronary stent placement: the Clopidogrel medco outcomes study. Pharmacotherapy. 2010;30:787-796.
10. United States Food and Drug Administration. FDA drug safety communication: early communication about an ongoing safety review of Clopidogrel bisulfate (marketed as Plavix). Available online at http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm.
11. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913-958. (Pubitemid 35168437)
12. Mega JL, Simon T, Anderson JL, et al. CYP2C19 genetic variants and clinical outcomes with Clopidogrel, a collaborative meta-analysis. Circulation. 2009;120:S598-S599.
13. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to Clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
14. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, Clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction results. Circulation. 2011;123:474-482.
15. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of Clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997.
16. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-1917.
17. Hsu PI, Lai KH, Liu CP Esomeprazole with Clopidogrel reduces peptic ulcer recurrence, compared with Clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011;140:791-798.
18. United States Food and Drug Administration. FDA drug safety communication: information on Clopidogrel bisulfate (marketed as Plavix). Available online at http://www.fda.gov/Drugs/DrugSafety/ucm190836.htm.
19. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105:2533-2549.
20. Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of Clopidogrel and proton pump inhibitors after percutaneous coronary intervention. AmJ Cardiol. 2011;107:871-878.
21. van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and gastrointestinal outcomes in Clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol. 2010;105:2430-2436; quiz 2437.
22. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influence of proton pump inhibitors on the antiplatelet potency of Clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol. 2010;56:532-539.